Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ENZN > SEC Filings for ENZN > Form 8-K on 25-Mar-2014All Recent SEC Filings

Show all filings for ENZON PHARMACEUTICALS INC

Form 8-K for ENZON PHARMACEUTICALS INC


25-Mar-2014

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or S


Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 19, 2014, Enzon Pharmaceuticals, Inc. (the "Company") received a letter (the "Notice") from the Listing Qualifications department of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that it no longer complies with the requirement to maintain a minimum of $10 million in stockholders' equity for continued listing on the Nasdaq Global Select Market as set forth in Nasdaq Listing Rule 5450(b)(1)(A). The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission on March 14, 2014 reported that the Company's total stockholders' equity as of December 31, 2013 was approximately $5.255 million. The Notice does not result in the immediate delisting of the Company's common stock from the NASDAQ Global Select Market. Rather, in accordance with Nasdaq Listing Rules, the Company has 45 calendar days from the date of the Notice to submit to Nasdaq a plan to regain compliance. If the Company submits a plan, Nasdaq will determine whether to accept the plan, considering such things as the likelihood that the plan will result in compliance with Nasdaq's continued listing criteria, the Company's past compliance history, the reasons for the Company's current non-compliance, other corporate events that may occur within the review period, the Company's overall financial condition and the Company's public disclosures. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the Notice for the Company to evidence compliance. If Nasdaq does not accept the plan, the Company will have the opportunity to appeal that decision to a NASDAQ Hearings Panel. However, there is no guarantee that the Company will be able to regain compliance with the listing requirements for continued listing on the Nasdaq Global Select Market or that its plan will be accepted by Nasdaq. Alternatively, the Company may consider applying to transfer its securities to the Nasdaq Capital Market. In order to transfer, the Company must meet the Nasdaq Capital Market's continued listing requirements, except for the bid price, and submit an on-line transfer application. The Company intends to submit an application to transfer the listing of its common stock to the Nasdaq Capital Market.

  Add ENZN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ENZN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.